Table 3.

Summary of articles on ovarian cancer.

Study	Chemotherapeutic Agent	Primary Investigation	Cohort Characteristics	Study cohort	Impact on OS	Impact on DFS	CC Coverage	PCI Coverage	Main Findings (with focus on peritoneal recurrence)
Spiliotis et al., 2014 (35)	Cisplatin and paclitaxel	RCT CRS + HIPEC vs CRSa	Recurrent OC with locally advanced disease (FIGO IIIc/IV)	120	Improved median OS in HIPEC group, 26.7 vs 13.4 months, p=0.006	Not covered	CC 0-2 included. OS significantly higher in CC 0, 30.9 vs 16.9 months, p=0.038	Mentioned, but not used as criteria for selection	No specific mention on recurrence
Driel et al., 2018 (OVHIPEC) (17)	Cisplatin	RCT CRS + HIPEC vs CRSa	Primary OC with significant abdominal disease/PM	245	Improved median OS in HIPEC group, 45.7 vs 33.9 months. Hazard ratio, p=0.02	Failed to achieve significance, RFS in HIPEC group, 14.2 vs 10.7 months	R-1 considered (complete cytoreduction, equivalent to CC 0)	Not covered	Reduced peritoneal recurrence in the HIPEC group given by increased median recurrence-free in the surgery-plus-HIPEC group (14.2 months vs. 10.7 months).
Ceresoli et al., 2018 (12)	Cisplatin and paclitaxel	PSM Cohort Study CRS + HIPEC vs CRSa	Primary OC with locally advanced disease (including PM)	56 after matching	Improved median OS in HIPEC group, no median reached in OS vs median 32.53 in control. (p=0.048)	No significance, median DFS of 13.96 months in HIPEC vs 13.23 months. (p=0.454)	CC 0-3, CC scores used for PS matching. 93% of HIPEC cohort was CC0.	Mentioned, but not used for selection nor PS matching	No significance in peritoneal recurrence amidst significantly improved OS in HIPEC. Peritoneal recurrence of 75% in HIPEC vs 82.1% in control (p=0.515), median DFS of 13.96 in HIPEC vs 13.23 months (p=0.454).